Immunogenicity and Safety Study of a Booster Dose of DTaP-IPV-Hep B-PRP~T Combined Vaccine at 15 to 18 Months of Age Following a Primary Series at 2, 3 and 4 Months of Age in Healthy Turkish Infants.
Phase of Trial: Phase III
Latest Information Update: 30 May 2014
At a glance
- Drugs Hib-DTaP-hepatitis B-poliovirus vaccine (Primary) ; Hepatitis B vaccine recombinant; Hib-DTaP-poliovirus vaccine
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics
- Sponsors Sanofi; sanofi pasteur
- 22 Jan 2010 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
- 22 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Mar 2008 New trial record.